

**AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of claims in the application.

1-9. (Canceled)

10. (Currently amended) An isolated nucleic acid molecule having a human ~~eye~~~~loo~~xygenases cyclooxygenase 2 promoter sequence operatively linked to a reporter ~~gene~~ polynucleotide, wherein the promoter sequence consists essentially of SEQ ID NO:5.

11. (Canceled)

12. (Currently amended) The nucleic acid molecule of claim 10, wherein the reporter ~~gene~~ polynucleotide is selected from the group consisting of a luciferase ~~gene~~ polynucleotide, a chloramphenicol acetyltransferase ~~gene~~ polynucleotide, and a  $\beta$ -galactosidase ~~gene~~ polynucleotide.

13. (Previously presented) The nucleic acid molecule of claim 10, wherein the nucleic acid molecule is contained in a vector.

14-17. (Canceled)

18. (Currently amended) A cell comprising an isolated nucleic acid molecule having a human ~~eye~~~~loo~~xygenases cyclooxygenase 2 promoter sequence operatively linked to a reporter ~~gene~~ polynucleotide, wherein the promoter sequence consists essentially of SEQ ID NO:5.

19. (Previously presented) The cell of claim 18, wherein the cell is a human cell.

20. (Previously presented) The cell of claim 19, wherein the cell is a Jurkat cell.

21. (Canceled)

22. (Currently amended) The cell of claim ~~21~~ 18, wherein the cell is capable of expressing the reporter gene.

23. (Previously presented) A cell line having the access number ECACC 9903245.

24. (Previously presented) An *Escherichia coli* DH5 cell line having the access number CECT 5145.

25-30. (Canceled)